
Sarepta Therapeutics, Inc.: shareholders and insiders
Price
$14.66
November 18, 2026Market cap $1.5B
What Ploutos Investor adds for Sarepta Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Sep 8, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$417.4K
2 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $123.2K by 1 person
- 2025: no buys, sold $294.2K by 1 person
- 2026: no buys, sold $123.2K by 1 person
- Sep 4, 2026Ryan Ho-Yan WongChief Financial OfficerKind
- Sep 4, 2026Ian Michael EstepanChief Operating OfficerKind
- Sep 4, 2026Cristin RothfussEVP, General CounselKind
- Sep 4, 2026Louise Rodino-KlapacPresident, R&D and Tech OpsKind
- Jul 28, 2026Michael SeverinoChief Executive OfficerKind
- Jun 4, 2026Kathryn Jean BoorDirectorKind
- Jun 4, 2026Stephen MayoDirectorKind
- Jun 4, 2026Hans Lennart Rudolf WigzellDirectorKind
- Jun 4, 2026M Kathleen BehrensDirectorKind
- Jun 4, 2026Deirdre P ConnellyDirectorKind
- Jun 4, 2026Claude NicaiseDirectorKind
- Jun 4, 2026Michael Andrew ChambersDirectorKind
- Jun 4, 2026Richard BarryDirectorKind
- Mar 12, 2026Stephen MayoKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Ryan Ho-Yan WongChief Financial Officer | 13.3K | $22.22 | $294.9K | Form 4 | |
| Sep 4, 2026 | Ian Michael EstepanChief Operating Officer | 24.8K | $22.22 | $551.0K | Form 4 | |
| Sep 4, 2026 | Cristin RothfussEVP, General Counsel | 22.0K | $22.22 | $489.4K | Form 4 | |
| Sep 4, 2026 | Louise Rodino-KlapacPresident, R&D and Tech Ops | 21.4K | $22.22 | $476.0K | Form 4 | |
| Jul 28, 2026 | Michael SeverinoChief Executive Officer | 756.1K | – | – | Form 4 | |
| Jun 4, 2026 | Kathryn Jean BoorDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Stephen MayoDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Hans Lennart Rudolf WigzellDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | M Kathleen BehrensDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Deirdre P ConnellyDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Claude NicaiseDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Michael Andrew ChambersDirector | 16.9K | – | – | Form 4 | |
| Jun 4, 2026 | Richard BarryDirector | 16.9K | – | – | Form 4 | |
| Mar 12, 2026 | Stephen Mayo | 7,239 | $17.02 | $123.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by SRPT's officers and directors from 2006 up to November 17, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class15.8%
- Vanguard Portfolio ManagementShare of class8.05%
- State StreetShare of class7.00%
- Vanguard Capital ManagementShare of class5.11%
- AQR Capital Management, LLCwith 1 more personShare of class5.05%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15.8% | 16.64M | Jul 30, 20262 filings since Jan 21, 2026 | 13G/A | |
| Vanguard Portfolio Management | 8.05% | 8.50M | Jul 31, 20262 filings since Apr 29, 2026 | 13G/A | |
| State Street | 7.00% | 7.41M | Nov 10, 20263 filings since Nov 10, 2025 | 13G | |
| Vanguard Capital Management | 5.11% | 5.37M | Apr 30, 2026 | 13G | |
| AQR Capital Management, LLCwith 1 more person | 5.05% | 5.33M | Aug 13, 20262 filings since Feb 13, 2026 | 13G/A |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Bridgewater (Dalio)In the quarter+292%
- Point72 (Cohen)In the quarter+58%
- Renaissance TechnologiesIn the quarter-59%
- Millennium Mgmt (Englander)In the quarter-74%
- AQR CapitalIn the quarter-91%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Bridgewater (Dalio) | 595.6K | +292% | $11M | 0.05% |
| Point72 (Cohen) | 805.8K | +58% | $15M | 0.02% |
| Renaissance Technologies | 454.3K | -59% | $8.3M | 0.01% |
| Millennium Mgmt (Englander) | 311.1K | -74% | $5.7M | 0.00% |
| AQR Capital | 395.7K | -91% | $7.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 21.3% of its shares outstanding were held short, -2.0% since the report before.
- Shares held short
- 22.33M
- 21.3%
- Since the report before22.78M on Sep 30, 2026
- -2.0%
- 7.5
- 2.99M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 81%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 4.45M
- Nov 15, 2023: Shares held short 4.25M
- Nov 30, 2023: Shares held short 4.26M
- Dec 15, 2023: Shares held short 4.71M
- Dec 29, 2023: Shares held short 4.69M
- Jan 12, 2024: Shares held short 5.68M
- Jan 31, 2024: Shares held short 5.17M
- Feb 15, 2024: Shares held short 4.81M
- Feb 29, 2024: Shares held short 4.78M
- Mar 15, 2024: Shares held short 4.97M
- Mar 28, 2024: Shares held short 4.60M
- Apr 15, 2024: Shares held short 4.87M
- Apr 30, 2024: Shares held short 5.69M
- May 15, 2024: Shares held short 6.56M
- May 31, 2024: Shares held short 6.49M
- Jun 14, 2024: Shares held short 9.46M
- Jun 28, 2024: Shares held short 9.56M
- Jul 15, 2024: Shares held short 7.33M
- Jul 31, 2024: Shares held short 6.72M
- Aug 15, 2024: Shares held short 6.73M
- Aug 30, 2024: Shares held short 6.53M
- Sep 13, 2024: Shares held short 6.15M
- Sep 30, 2024: Shares held short 6.19M
- Oct 15, 2024: Shares held short 5.66M
- Oct 31, 2024: Shares held short 5.60M
- Nov 15, 2024: Shares held short 5.04M
- Nov 29, 2024: Shares held short 5.82M
- Dec 13, 2024: Shares held short 5.59M
- Dec 31, 2024: Shares held short 5.13M
- Jan 15, 2025: Shares held short 4.98M
- Jan 31, 2025: Shares held short 5.05M
- Feb 14, 2025: Shares held short 4.92M
- Feb 28, 2025: Shares held short 5.06M
- Mar 14, 2025: Shares held short 4.85M
- Mar 31, 2025: Shares held short 6.10M
- Apr 15, 2025: Shares held short 6.62M
- Apr 30, 2025: Shares held short 6.70M
- May 15, 2025: Shares held short 8.83M
- May 30, 2025: Shares held short 9.26M
- Jun 13, 2025: Shares held short 9.89M
- Jun 30, 2025: Shares held short 14.68M
- Jul 15, 2025: Shares held short 14.86M
- Jul 31, 2025: Shares held short 20.95M
- Aug 15, 2025: Shares held short 18.24M
- Aug 29, 2025: Shares held short 20.31M
- Sep 15, 2025: Shares held short 20.28M
- Sep 30, 2025: Shares held short 19.62M
- Oct 15, 2025: Shares held short 17.69M
- Oct 31, 2025: Shares held short 17.31M
- Nov 14, 2025: Shares held short 18.00M
- Nov 28, 2025: Shares held short 19.57M
- Dec 15, 2025: Shares held short 20.16M
- Dec 31, 2025: Shares held short 20.46M
- Jan 15, 2026: Shares held short 21.28M
- Jan 30, 2026: Shares held short 22.22M
- Feb 13, 2026: Shares held short 22.20M
- Feb 27, 2026: Shares held short 21.24M
- Mar 13, 2026: Shares held short 22.89M
- Mar 31, 2026: Shares held short 25.73M
- Apr 15, 2026: Shares held short 25.33M
- Apr 30, 2026: Shares held short 24.92M
- May 15, 2026: Shares held short 25.02M
- May 29, 2026: Shares held short 25.13M
- Jun 15, 2026: Shares held short 25.17M
- Jun 30, 2026: Shares held short 28.73M
- Jul 15, 2026: Shares held short 28.49M
- Jul 31, 2026: Shares held short 27.57M
- Aug 14, 2026: Shares held short 27.05M
- Aug 31, 2026: Shares held short 24.62M
- Sep 15, 2026: Shares held short 25.43M
- Sep 30, 2026: Shares held short 22.78M
- Oct 15, 2026: Shares held short 22.33M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading45.8% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 45.8% of the shares in the reported trades were short sales, against 54.2% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 45.8%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 54.2%
- Change
- -8.4 pts
- Short sales a dayon average, of 612.0K shares
- 280.4K
- More than atof 3,666 US-listed companies, same days
- 35%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 74%
- Oct 12, 2026: Short sales 71.6%
- Oct 13, 2026: Short sales 57.6%
- Oct 14, 2026: Short sales 54.4%
- Oct 15, 2026: Short sales 40.2%
- Oct 16, 2026: Short sales 52.7%
- Oct 19, 2026: Short sales 44.2%
- Oct 20, 2026: Short sales 53.2%
- Oct 21, 2026: Short sales 46.1%
- Oct 22, 2026: Short sales 48.2%
- Oct 23, 2026: Short sales 48.7%
- Oct 26, 2026: Short sales 44.5%
- Oct 27, 2026: Short sales 59.1%
- Oct 28, 2026: Short sales 53.2%
- Oct 29, 2026: Short sales 48.3%
- Oct 30, 2026: Short sales 55.2%
- Nov 2, 2026: Short sales 51.7%
- Nov 3, 2026: Short sales 49.2%
- Nov 4, 2026: Short sales 47.6%
- Nov 5, 2026: Short sales 45.3%
- Nov 6, 2026: Short sales 47.8%
- Nov 9, 2026: Short sales 32.7%
- Nov 10, 2026: Short sales 35.6%
- Nov 11, 2026: Short sales 49.9%
- Nov 12, 2026: Short sales 48.5%
- Nov 13, 2026: Short sales 50.2%
- Nov 16, 2026: Short sales 55.2%
- Nov 17, 2026: Short sales 49.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Richard BarryDirectorDirectly3.23M
- Michael SeverinoChief Executive OfficerDirectly756.1K
- Michael Andrew ChambersDirectorDirectly243.9K
- M Kathleen BehrensDirectorDirectly224.4K
- Louise Rodino-KlapacPresident, R&D and Tech OpsDirectly203.9K
- Ian Michael EstepanChief Operating OfficerDirectly177.2K
- Ryan Ho-Yan WongChief Financial OfficerDirectly121.8K
- Cristin RothfussEVP, General CounselDirectly115.5K
- Claude NicaiseDirectorDirectly48.4K
- Hans Lennart Rudolf WigzellDirectorDirectly42.1K
- Kathryn Jean BoorDirectorDirectly25.1K
- Ryan Edward BrownEVP, General CounselDirectly23.5K
- Deirdre P ConnellyDirectorDirectly22.1K
- Stephen MayoDirectorDirectly18.6K
- Dallan MurrayChief Customer OfficerDirectly18.1K
- Bilal ArifChief Tech Ops OfficerDirectly17.4K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Richard BarryDirector | 3.23M | – | Jun 4, 2026 | Form 4 |
| Michael SeverinoChief Executive Officer | 756.1K | – | Jul 28, 2026 | Form 4 |
| Michael Andrew ChambersDirector | 243.9K | 260.1K | Jun 4, 2026 | Form 4 |
| M Kathleen BehrensDirector | 224.4K | – | Jun 4, 2026 | Form 4 |
| Louise Rodino-KlapacPresident, R&D and Tech Ops | 203.9K | – | Sep 4, 2026 | Form 4 |
| Ian Michael EstepanChief Operating Officer | 177.2K | – | Sep 4, 2026 | Form 4 |
| Ryan Ho-Yan WongChief Financial Officer | 121.8K | – | Sep 4, 2026 | Form 4 |
| Cristin RothfussEVP, General Counsel | 115.5K | – | Sep 4, 2026 | Form 4 |
| Claude NicaiseDirector | 48.4K | – | Jun 4, 2026 | Form 4 |
| Hans Lennart Rudolf WigzellDirector | 42.1K | – | Jun 4, 2026 | Form 4 |
| Kathryn Jean BoorDirector | 25.1K | – | Jun 4, 2026 | Form 4 |
| Ryan Edward BrownEVP, General Counsel | 23.5K | – | Jun 25, 2024 | Form 4 |
| Deirdre P ConnellyDirector | 22.1K | – | Jun 4, 2026 | Form 4 |
| Stephen MayoDirector | 18.6K | – | Jun 4, 2026 | Form 4 |
| Dallan MurrayChief Customer Officer | 18.1K | – | May 2, 2024 | Form 4 |
| Bilal ArifChief Tech Ops Officer | 17.4K | – | Jun 25, 2024 | Form 4 |
A lower bound: it counts only the 16 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.75%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.45%
- IBBiShares Biotechnology ETFWeight in the fund0.14%
- IJTiShares S&P Small-Cap 600 Growth ETFWeight in the fund0.13%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.11%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.10%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.10%
- IJSiShares S&P Small-Cap 600 Value ETFWeight in the fund0.08%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.07%
- IWMiShares Russell 2000 ETFWeight in the fund0.06%
29 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 322
- Q4 2025: Managers 348
- Q1 2026: Managers 347
- Q2 2026: Managers 323
Institutional investors by quarter
The fund managers holding SRPT, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 323 managers held 108M shares, worth $1.9B. During the quarter 49 opened a position, 73 closed one, 96 added and 116 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+29%
- State StreetIn the quarter+35%
- Vanguard Portfolio ManagementIn the quarter+26%
- Two Sigma InvestmentsIn the quarter+0.1%
- Vanguard Capital ManagementIn the quarter+0.3%
- First Trust AdvisorsIn the quarter+5.6%
- AQR CapitalIn the quarter-33%
- Geode Capital ManagementIn the quarter+39%
- Erste Asset ManagementIn the quarter-13%
- Marshall WaceIn the quarter+204%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 18.99M | +29% | $341M |
| State Street | 8.92M | +35% | $160M |
| Vanguard Portfolio Management | 8.38M | +26% | $151M |
| Two Sigma Investments | 4.60M | +0.1% | $83M |
| Vanguard Capital Management | 4.59M | +0.3% | $83M |
| First Trust Advisors | 4.37M | +5.6% | $78M |
| AQR Capital | 4.33M | -33% | $77M |
| Geode Capital Management | 2.77M | +39% | $50M |
| Erste Asset Management | 2.57M | -13% | $46M |
| Marshall Wace | 2.21M | +204% | $40M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Sarepta Therapeutics's filings show?
Who buys and sells is one part of Sarepta Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have SRPT's insiders bought or sold?
From Jun 5, 2026 to Sep 8, 2026 Sarepta Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold SRPT?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $15M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.